Source: Eur Respir J, 54 (3) 1900161; 10.1183/13993003.00161-2019
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Lutz Wollin, Jörg H.W. Distler, Elizabeth F. Redente, David W.H. Riches, Susanne Stowasser, Rozsa Schlenker-Herceg, Toby M. Maher, Martin Kolb. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J, 54 (3) 1900161; 10.1183/13993003.00161-2019

Member's Comments

No comment yet.

Related content which might interest you: Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019 Year: 2019 Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019 Antifibrotic treatment in progressive non-IPF fibrotic interstitial lung diseases Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Antifibrotics effects of nintedanib on lung fibroblasts derived from patients with progressive fibrosing intertitial lung diseases Source: Virtual Congress 2020 – Translational therapeutic advances Year: 2020 Prevalence of progressive fibrosing interstitial lung disease Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 Genetic susceptibilty and manifestation of progressive fibrosing interstitial lung diseases. Source: Virtual Congress 2020 – New clinical insights into idiopathic pulmonary fibrosis Year: 2020 Experience with antifibrotics treatment in progressive interstitial lung diseases non-IPF Source: Virtual Congress 2021 – Clinical evolution, management and outcomes of patients with rare diffuse parenchymal lung diseases Year: 2021 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 The natural history of progressive fibrosing interstitial lung diseases Source: Eur Respir J, 55 (6) 2000085; 10.1183/13993003.00085-2020 Year: 2020 Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis Source: Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019 Year: 2019 Clubbing in patients with fibrotic interstitial lung diseases Source: International Congress 2017 – ILDs: clinical problems Year: 2017 Rituximab in severe, treatment-refractory interstitial lung disease Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Genetics variants in familial interstitial pneumonia and progressive fibrosing interstitial lung disease (PF-ILD) Source: Virtual Congress 2021 – Genetics and translational aspects of idiopathic pulmonary fibrosis Year: 2021 Interstitial lung diseases and systemic disorders with lung involvement Source: ERS Skills Course 2017 - Summer school of paediatric respiratory medicine Year: 2017 Interstitial lung diseases and systemic disorders with lung involvement Source: ERS Skills Course 2016 Year: 2016 Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype Source: Eur Respir Rev, 27 (150) 180077; 10.1183/16000617.0077-2018 Year: 2018 Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease Source: International Congress 2016 – ILD pathogenesis Year: 2016 Clinical course and outcomes of acute exacerbation of fibrosing interstitial lung disease Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Genetics of fibrosing lung diseases Source: Eur Respir J 2005; 25: 915-927 Year: 2005